Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

FSANZ clears the way for BLIS M18 probiotic use in foods

From: BLIS Technologies Ltd (NZX:BLT)

Date: Thursday, 17 Jan 2013

Release: Immediate


FSANZ clears the way for BLIS M18™ probiotic use in foods


BLIS Technologies Ltd (NZX:BLT) is pleased to advise that it has received a written acknowledgement from Food Standards Australia New Zealand (‘FSANZ’) that its new probiotic, BLIS M18™ is not considered by the authority to be a Novel Food in either Australia or New Zealand. This enables the BLIS M18™ probiotic to be used directly in food applications such as yoghurt and beverages, in Australia and New Zealand bypassing the demanding and formal “novel foods” application.

By definition, a novel food is a non-traditional food that has no sufficient history of safe use and so in making this declaration, FSANZ have acknowledged the intrinsic safety of the BLIS M18™ probiotic in humans, as well as the safety of the species and the strain that BLIS M18™ originates from.

Novel food ingredients however, can be sold in Australia and New Zealand but only after they have under gone a rigorous risk and safety assessment by the researchers and food scientists within FSANZ. Once assessed and deemed to be safe, these novel foods are then added to the novel foods list, which makes up the Novel Foods Standard. Only food ingredients that appear on this list or have been assessed prior to be a non-novel food ingredient (such as the BLIS M18™ and BLIS K12® probiotics) can be legally sold as a food ingredient, in either Australia or New Zealand.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Dr Barry Richardson, CEO of BLIS Technologies said today, “We welcome the finding by the Advisory Committee on Novel Foods to indicate the ‘non-novel food’ status to BLIS M18™. This probiotic, like its partner product BLIS K12®, has an exceptional safety record and has been part of our food supply for a long time. This decision from FSANZ will now enable us to discuss the application of both these probiotics with food manufacturers who are seeking to assist with their consumer’s oral health and to fight tooth decay in children”

About BLIS M18™
BLIS M18™ is an oral cavity probiotic, which has been shown to support the teeth and gums. BLIS M18™ is able to protect itself from other invading bacteria by secreting specific short-chain proteins or peptides known as “BLIS”. BLIS stands for Bacteriocin-Like-Inhibitory- Substances and that is why BLIS probiotics are sometimes called “Next Generation, Advanced Probiotics”.

ENDS

www.blis.co.nz

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
GenPro: General Practices Begin Issuing Clause 14 Notices

GenPro has been copied into a rising number of Clause 14 notices issued since the NZNO lodged its Primary Practice Pay Equity Claim against General Practice employers in December 2023.More

SPADA: Screen Industry Unites For Streaming Platform Regulation & Intellectual Property Protections

In an unprecedented international collaboration, representatives of screen producing organisations from around the world have released a joint statement.More

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.